Announcements & Circulars-Alphamab Oncology

English 中文简体中文繁体

English 中文简体中文繁体

Investors

Information Disclosure

Listing Documents

Financial Reports

Announcements & Circulars

Company Presentation

Corporate Governance

Stock Information

Corporate Communications

Email Subscription

Announcements & Circulars

The announcement begins in December 2019

ADOPTION OF POST-IPO SHARE OPTION SCHEME 2020-04-14
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2020 2020-04-03
CONNECTED TRANSACTION ANNOUNCEMENT - TECHNOLOGY DEVELOPMENT AGREEMENT WITH SUZHOU ALPHAMAB ON PROCESS OPTIMIZATION AND TRANSFER OF KN019, KN026 AND KN035 AND TECHNOLOGY DEVELOPMENT AGREEMENT WITH SUZHOU ALPHAMAB ON PROCESS SCALE-UP RESEARCH OF KN052 2020-03-31
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2019 2020-03-31
INSIDE INFORMATION ANNOUNCEMENT - COLLABORATIVE AGREEMENT WITH SIMCERE PHARMACEUTICAL AND 3D MEDICINES FOR KN035 AND SUPPLEMENTAL AGREEMENTS TO THE KN035 CO-DEVELOPMENT AGREEMENT 2020-03-30
VOLUNTARY ANNOUNCEMENT - COLLABORATION WITH PFIZER ON KN026 IN COMBINATION WITH IBRANCE(PALBOCICLIB) IN HER2+ BREAST CANCER 2020-03-27
DATE OF BOARD MEETING 2020-03-18
Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2020 2020-03-04
VOLUNTARY ANNOUNCEMENT - FOUR IND APPLICATIONS ACCEPTED BY NMPA CDE FOR TWO ANTI-TUMOR BISEPECIFIC ANTIBODIES IN PIPELINE 2020-02-20
VOLUNTARY ANNOUNCEMENT - JIANGSU ALPHAMAB PASSED ON-SITE INSPECTION OF EU QUALIFIED PERSON 2020-02-07

23 24 25 26 27 28